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Specific phosphoinositide lipids promote cell growth and cancer. In this issue of Cancer Cell, Fayngerts and
colleagues demonstrate that the TIPE3 protein enhances PtdIns(4,5)P2 and PtdIns(3,4,5)P3, is overexpressed
in certain cancers, and promotes tumorigenesis. TIPE3 can act as a lipid transfer protein andmay constitute a
novel phosphoinositide metabolism regulator.Phosphoinositides are a minor compo-
nent of lipid membranes, yet they play
key roles in many cellular functions from
vesicle trafficking and motility to cell
survival, with disruption of phospholipid
homeostasis being linked to various hu-
man diseases (Balla, 2013; Billcliff and
Lowe, 2014). In particular, deregulation
of PtdIns(3,4,5)P3 and, to a lesser extent,
PtdIns(4,5)P2 production has been clearly
shown to promote cell survival and tumor
progression. In fact, activating muta-
tions in the lipid kinase PIK3CA, which
phosphorylates PtdIns(4,5)P2 to generate
PtdIns(3,4,5)P3 and loss-of-function in
the PtdIns(3,4,5)P3 phosphatase PTEN,
are among the most common genetic
changes found in cancer.
PtdIns(3,4,5)P3 recruits pleckstrin ho-
mology (PH) domain-containing pro-
teins, such as PDK1 and AKT, to the
plasma membrane. Subsequent activa-
tion of AKT leads to phosphorylation of
numerous substrates, including proteins
involved in protein synthesis (TSC2,
PRAS40), survival (FOXO, MDM2), and
cell cycle progression (GSK3, p21) (Mann-
ing and Cantley, 2007).
PtdIns(4,5)P2 is much more abundant
than the transiently produced PtdIns
(3,4,5)P3 and can bind a large number of
proteins by interacting with PH or FERM
domains or polybasic stretches among
others. PtdIns(4,5)P2 is the precursor
for PtdIns(3,4,5)P3 production. In addi-
tion, it is cleaved by phospholipase C
(PLC) into inositol-triphosphate and diac-
ylglycerol, leading to calcium release and
activation of protein kinase C family mem-
bers, both of which have numerous and
often context-dependent effects (Bunney
and Katan, 2010). In addition, PtdIns(4,5)
P2 plays important roles in endocytosis
and cytoskeletal organization through the
effects of PtdIns(4,5)P2-binding proteins.Simplistically, proteins involved in
phosphoinositide signaling can be
divided into three categories. (1) Phos-
phoinositide-modifying enzymes: these
include lipid kinases (e.g., PI3Ks), lipid
phosphatases (PTEN, SHIP), and phos-
pholipases (e.g., PLCs), which generate
new lipid species and initiate and termi-
nate signaling cascades. (2) Lipid binding
proteins: proteins that contain lipid bind-
ing domains such as PH, FERM, and PX
domains or poly-basic motifs can act as
effectors downstream of different lipid
species. In this issue of Cancer Cell,
Fayngerts et al. (2014) have characterized
a protein, TIPE3, which acts as a transfer
protein for PtdIns(4,5)P2 and falls into a
third category: (3) proteins that transfer,
present, and protect lipids.
TIPE3 is a previously uncharacterized
member of the tumor necrosis factor-
a-induced protein 8 (TNFAIP8 or TIPE)
family of proteins that are involved in
tumorigenesis and inflammation (Lou and
Liu, 2011). Fayngerts et al. (2014) show
that TIPE3 may also promote tumorigen-
esis through elevation of PtdIns(4,5)P2
and PtdIns(3,4,5)P3 levels. They use
immunohistochemistry to demonstrate
that TIPE3 expression is upregulated
in human cancers, including lung and
esophageal cancers. Consistently, TIPE3
overexpression promotes cell and tumor
growth in an NIH 3T3-HRasV12 mouse
xenograft model, while TIPE3 knockout
mice exhibit delayed carcinogen-induced
tumorigenesis. Combined with data from
soft agar assays, cell cycle profiles, and
cap-dependent translation, TIPE3 clearly
promotes cell growth and cell survival.
This is in contrast to other members of
the TNFAIP8 family, which have been
shown to decrease cell survival (Gus-
Brautbar et al., 2012; Lou and Liu, 2011).
Fayngerts et al. (2014) hypothesize thatCancer Cell 26this difference in function may be ac-
counted for by a unique N-terminal region
present in TIPE3. Indeed, deletion of this
region converts TIPE3 from a pro-survival
to a pro-death protein, while fusion of the
N-terminal region to TIPE2 inhibits its
pro-death function.
Fayngerts et al. (2014) observe that
ectopic expression of TIPE3 enhanced
activating phosphorylations on AKT and
MAPK, while knockdown had the oppo-
site effect. Interestingly, this is depen-
dent on PI3K and PLC activity, suggesting
a role for TIPE3 in enhancing cellular
PtdIns(4,5)P2 and PtdIns(3,4,5)P3 levels.
Consistent with this hypothesis, TIPE3
overexpression leads to enhanced levels
of both lipids, measured by lipid overlay
assays and confocal imaging. That this
is a direct effect of TIPE3 is suggested
by the fact that forced nuclear localization
of TIPE3 increased nuclear PtdIns(4,5)P2
levels.
In order to understand how TIPE3 was
enhancing phosphoinositide levels, the
crystal structure of TIPE3 was deter-
mined. Similar to other TNFAIP8 family
members, TIPE3 contains a TH fold,
which has a large hydrophobic cavity,
suggesting the ability to bind lipophilic
molecules. Indeed, by lipid overlay
assay, TIPE3 (as well as TIPE1, TIPE2,
and TNFAIP8) are able to bind a num-
ber of lipid species, most prominently
PtdIns(4,5)P2, PtdIns(3,5)P2, PtdIns(3,4)
P2, and PtdIns(3,4,5)P3. Importantly, this
is dependent on the TH domain, because
mutation within the hydrophobic cavity
disrupts this binding as well as the ability
of TIPE3 to promote PtdIns(3,4,5)P3 levels
and AKT activation.
TIPE3 thus has the ability both to bind
and enhance phosphoinositide levels.
There is no evidence that TIPE3 is a
lipid-generating enzyme, suggesting that, October 13, 2014 ª2014 Elsevier Inc. 443
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Previewsthe TH domain may either protect the
lipids from being turned over or enhance
production of certain lipid species. Fayng-
erts et al. (2014) explore this latter possi-
bility and demonstrate that, in vitro,
TIPE3 can bind to vesicles containing
PtdIns(4,5)P2 and intriguingly can act as
a lipid transfer protein. TIPE3 is able to
both extract PtdIns(4,5)P2 from vesicles
as well as insert solubilized PtdIns(4,5)P2
into vesicles. Therefore, TIPE3 (and
possibly the rest of the TNFAIP8 family)
may represent a new class of phospho-
lipid transfer proteins.
Phospholipid transfer proteins mediate
themovement of phospholipids (including
phosphatidylcholine, phosphatidylinosi-
tol, and sterols) between membranes
and function as lipid sensors or present-
ing proteins (Wirtz, 2006). Phosphati-
dylinositol transfer proteins have been
previously shown to have essential roles
in organism survival, and, through intra-
cellular transfer of the precursor mole-
cule, PI, can have knock-on effects on
the production of other lipid species
including PtdIns(4,5)P2 and PtdIns(3,4,5)
P3 (Chang et al., 2013; Wirtz, 2006). How-
ever, to our knowledge, TIPE3 is the
first transfer protein described that binds
and transfers PtdIns(4,5)P2. It will be
important to determine if the function of
other TNFAIP8 family members is at least
partially dependent on their ability to bind
phospholipids.444 Cancer Cell 26, October 13, 2014 ª2014Mechanistically, this study opens up
many questions about how exactly
TIPE3 enhances lipid production. The
authors most thoroughly address the
role of TIPE3 in binding and regulating
PtdIns(4,5)P2. However TIPE3 was shown
to bind a wider range of phospholipids,
and it will be important to address the
effect of TIPE3 on the metabolism of
these lipid species. In addition, the
exact function of TIPE3 in lipid meta-
bolism is unclear. Because the major
source of PtdIns(4,5)P2 is within the
plasma membrane, is TIPE3 changing
the local concentrations of PtdIns(4,5)
P2? Or is the major function of TIPE3 to
transfer a precursor phospholipid from
elsewhere in the cell to the plasma mem-
brane, where it can then be converted
to PtdIns(4,5)P2?
Alternatively, is the major physiological
function of TIPE3 to act as a lipid present-
ing protein? This is currently a source of
debate in the field of lipid transfer proteins
and has proved a difficult question to
answer in vivo. Fayngerts et al. (2014) pro-
vide some evidence that TIPE3 can func-
tion as a lipid-presenting protein; as in an
in vitro lipid kinase assay, TIPE3 enhances
PtdIns(3,4,5)P3 production by PI3K.
Taken together, the identification of
TIPE3 introduces us to a new class of lipid
regulators that can directly regulate the
levels of PtdIns(4,5)P2 and PtdIns(3,4,5)
P3. Future work will be important toElsevier Inc.assess the exact mechanism of action,
not only from a lipid biochemistry
perspective, but also in biology, signaling,
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